Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Clinically Relevant Drug Product Specifications: Methods of Establishment

Clinically Relevant Drug Product Specifications: Methods of Establishment

Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...

Preclinical Development: Overview

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Derivation expansion of the general solubility equation (GSE).

Journal of pharmaceutical sciences·2026

Same author

Targeting Soluble Adenylyl Cyclase for On-Demand Contraception.

Physiology (Bethesda, Md.)·2026

Same author

High performance sorting of motor unit action potentials with EMUsort.

bioRxiv : the preprint server for biology·2026

Same author

A cluster of articles in memory of Rodolfo Pinal, Ph.D.

Journal of pharmaceutical sciences·2025

Same author

Myomatrix arrays for high-definition muscle recording.

eLife·2023

Same author

Myomatrix arrays for high-definition muscle recording.

bioRxiv : the preprint server for biology·2023

Search research articles

Related Experiment Video

Updated: May 22, 2026

A Workflow for Lipid Nanoparticle (LNP) Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models (SVEM)

A Workflow for Lipid Nanoparticle (LNP) Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models (SVEM)

Published on: August 18, 2023

Preformulation study of NSC-726796.

Duoli Guo¹, James P Cain, Sean O'Connell

¹College of Pharmacy, University of Arizona, Tucson, Arizona 85721, USA. duoliguo@gmail.com

AAPS Pharmscitech

|May 4, 2012

Summary

This summary is machine-generated.

A stability-indicating HPLC method was developed to analyze 2-(2,4-difluorophenyl)-4,5,6,7-tetrafluoroisoindoline-1,3-dione (NSC-726796) and its degradation products. The drug is most stable at pH 1 and its key degradant lacks antiangiogenic activity.

More Related Videos

Preparation and Characterization of Individual and Multi-drug Loaded Physically Entrapped Polymeric Micelles

Preparation and Characterization of Individual and Multi-drug Loaded Physically Entrapped Polymeric Micelles

Published on: August 28, 2015

Formulation and Characterization of Bioactive Agent Containing Nanodisks

Formulation and Characterization of Bioactive Agent Containing Nanodisks

Published on: March 17, 2023

Related Experiment Videos

Last Updated: May 22, 2026

A Workflow for Lipid Nanoparticle (LNP) Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models (SVEM)

A Workflow for Lipid Nanoparticle (LNP) Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models (SVEM)

Published on: August 18, 2023

Preparation and Characterization of Individual and Multi-drug Loaded Physically Entrapped Polymeric Micelles

Preparation and Characterization of Individual and Multi-drug Loaded Physically Entrapped Polymeric Micelles

Published on: August 28, 2015

Formulation and Characterization of Bioactive Agent Containing Nanodisks

Formulation and Characterization of Bioactive Agent Containing Nanodisks

Published on: March 17, 2023

Area of Science:

Analytical Chemistry
Medicinal Chemistry
Pharmacology

Background:

2-(2,4-difluorophenyl)-4,5,6,7-tetrafluoroisoindoline-1,3-dione (NSC-726796) exhibits antiangiogenic properties.
Understanding the stability and degradation of pharmaceutical compounds is crucial for drug development and efficacy.
Identifying degradation products is essential for assessing drug safety and potential loss of activity.

Purpose of the Study:

To develop a stability-indicating HPLC method for quantifying NSC-726796 and its primary degradants.
To investigate the degradation kinetics and mechanism of NSC-726796.
To identify the chemical structures of the main degradation products and assess their biological activity.

Main Methods:

High-performance liquid chromatography (HPLC) was employed for method development and quantification.
Degradation studies were conducted under various conditions to determine kinetics and mechanism.
Mass spectrometry or other spectroscopic techniques were likely used for structural elucidation of degradation products (implied).

Main Results:

A validated stability-indicating HPLC method was successfully developed.
The degradation of NSC-726796 follows first-order kinetics and is base-catalyzed, with optimal stability observed at pH 1.
Three main degradation products were identified: 2-(2,4-difluorophenylcarbamoyl)-3,4,5,6-tetrafluorobenzoic acid (NSC-749820), 2,4-difluoroaniline, and tetrafluorophthalic acid.
NSC-726796 also reacted with methanol and ethanol.
The identified degradant NSC-749820 did not exhibit antiangiogenic activity.

Conclusions:

The developed HPLC method is suitable for monitoring the stability of NSC-726796.
NSC-726796 exhibits limited stability in basic conditions and can degrade via hydrolysis and reaction with alcohols.
The loss of antiangiogenic activity in a major degradation product (NSC-749820) highlights the importance of stability studies for maintaining therapeutic efficacy.